Open AccessIBD5 polymorphisms in inflammatory bowel disease: Association with response to infliximab
Author(s) -
Elena Urcelay,
Juan L. Mendoza,
Alfonso Martín Martínez,
Laura Fernández,
Carlos Taxonera,
Manuel DíazRubio,
Emilio G. de la Concha
Publication year - 2005
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v11.i8.1187
Subject(s) - infliximab , inflammatory bowel disease , ulcerative colitis , genotype , crohn's disease , locus (genetics) , allele , medicine , gastroenterology , nod2 , case control study , odds ratio , immunology , disease , genetics , biology , gene
Inflammatory bowel diseases (IBD) are multifactorial pathologies of unknown etiology. One susceptibility locus, IBD5, has been mapped to chromosome 5q31. We analyzed our Spanish cohorts of Crohn's disease (CD) and ulcerative colitis (UC) patients to determine whether this locus is associated with IBD, and to ascertain the main clinical phenotype influenced by this risk factor. The kind of interaction, either genetic heterogeneity or epistasis, between this IBD5 susceptibility region and the NOD2/CARD15 gene mutations was studied as well. Finally, we assessed whether this locus can predict response to infliximab therapy.